ZARZA We are Zarza, the prestigious firm behind major projects in information technology.

The Beacon (Audio)

The Beacon (Audio)

Por: H. Jack West, MD

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

75 episodios disponibles

Latest episodes of the podcast The Beacon (Audio)

Mostrando página 4 de 4

Are the PD-1/PD-L1 Immune Checkpoint Inhibitors Completely Interchangeable in Lung Cancer Management? (BMIC-015) 13/11/2017

Will Immunotherapy Shift the Balance of Treatment for Borderline Resectable Stage III NSCLC Away from Surgery? (BMIC-014) 10/11/2017

Research Question or Standard of Care: The Barriers to Broad Adoption in Cancer Care (BMIC-013) 30/10/2017

Hyper-Progressive Disease on Immunotherapy in Advanced NSCLC (BMIC-012) 27/10/2017

Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011) 20/10/2017

How Should We Monitor Patients After Potentially Curative Surgery for Lung Cancer? Some Actual Evidence, at Long Last (BMIC-010) 29/09/2017

Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009) 25/09/2017

Do Patients with Advanced NSCLC Doing Well on an Immune Checkpoint Inhibitor Reach a Point of Diminishing Returns after a Fixed Duration of Treatment? (BMIC-008) 13/09/2017

The FLAURA Trial: Practice-Changing Results for Patients with EGFR Mutation-Positive NSCLC (BMIC-007) 11/09/2017

Immunotherapy in Stage III NSCLC: The Practice-Changing Results of the PACIFIC Trial Usher in a New Standard (BMIC-006) 09/09/2017

Is There Still a Value in Testing for PD-L1 Expression in Advanced NSCLC Today? (BMIC-005) 05/09/2017

Better Communication Leads to Better Outcomes for Cancer Patients (BMIC-004) 03/09/2017

Are Two Immunotherapy Agents Better than One? Will the MYSTIC Trial Prove to Be a Mistake? (BMIC-003) 29/08/2017

Early Returns on the FLAURA Trial: Should Osimertinib be a First Line Agent in EGFR Mutation-Positive NSCLC? (BMIC-002) 29/08/2017

Importing Immunotherapy into the Curative Setting for NSCLC: The Potential Implications of the PACIFIC Trial (BMIC-001) 29/08/2017

« Primera ‹ Anterior 1 2 3 4